3rd Rare Disease Collaboration Summit

Listening to the voice of the patient has become a top priority in clinical trials, particularly so in rare disease studies. The greater emphasis on patient-centric care and early engagement has been critical to R&D and pre-commercialization activities. A proven win-win for patients and sponsors alike, these collaborations lead to better protocols and trials that more effectively fit the needs of the community.

ExL Pharma’s 3rd Rare Disease Collaboration Summit gives you the tools you need to build lasting partnerships with patient advocacy groups in order to construct more flexible and patient-centric clinical trial protocols and accelerate the regulatory approval of your orphan drug. This event hosts the formation of working group relationships that harness the collective resources of industry and patient advocates, creating a working framework for shaping legislation and convincing regulators. Build best practice outputs that outlive the meeting!

Top Five Reasons to Attend

1. Pinpoint opportunities to fast-track evidence-based treatments to patients
2. Gather strategies for identifying patient-centered clinical endpoints
3. Learn about success stories involving pharma/patient partnerships and accelerated clinical trials
4. Uncover strategies to involve the patient early and often throughout the life cycle of drug development and implementation
5. Benefit from updates on the regulatory guidelines determining the clinical and market access development potential for orphan drugs

Who Should Attend

This conference is designed for representatives from pharmaceutical, biotechnology and medical device companies as well as members of the rare disease community with responsibilities in the following areas: